Skip to content
22decisions home

Research brief · HLS-09

Build, Buy, or Partner? AI Sourcing Choices in Healthcare

In editorial reviewPlanned publish date: 26 November 2026
Theme
Value and cost
For
CIO, CTO
The decision
Build, buy, or partner?

Summary

Build, buy, or partner? We map how healthcare and life sciences decision units approach this choice: who decides, who can veto, what AI leaders are doing differently, and what it means for the technology partners they buy from.

The short answer

In healthcare and life sciences, the decision to build, buy, or partner for AI is led by the CIO and the CTO, but the CFO can stop it. In healthcare and life sciences, validation requirements and patient-data rules push many organisations towards partners and validated platforms rather than building from scratch. A typical large healthcare and life sciences organisation involves around 11.1 executives in AI decisions.

Key questions

  • Which AI capabilities should healthcare and life sciences organisations build, buy, or partner for?
  • Who makes the sourcing decision, and who can veto it?
  • How do AI leaders in healthcare and life sciences source differently from laggards?
  • What do buyers expect from AI vendors and services firms?

Headline finding

In 53% of modelled healthcare and life sciences organisations, the CFO who can veto AI sourcing is a cautious Steward or Sceptic.

Calibrated modelCalibrated model.

What the full report covers

  • Who is involved in this decision, who decides, and who can say no
  • How AI leaders approach it differently from laggards
  • What technology leaders should do next
  • What it means for the technology and services partners they buy from

Full report: 8 to 10 pages, PDF.

Evidence basis

  • Calibrated model
  • Cited

How we label evidence is explained in our methodology.

Frequently asked questions

Who decides how to build, buy, or partner for AI in healthcare and life sciences?
In our decision-rights model, the CIO and the CTO decide, with input from the wider decision unit (Calibrated model).
Who can veto it?
The CFO can approve or block the decision (Calibrated model).
How much are healthcare and life sciences companies hiring for AI?
AI roles make up 1.2% of current job postings at large US healthcare and life sciences companies, with 69 senior AI roles and 7 AI-governance roles (Measured, October 2026).

Get it first

This brief is planned for 26 November 2026. Request early access and we'll send it to you as soon as it is ready.

The same decision in other industries

More from Healthcare & Life Sciences

Get our research in your inbox

One considered briefing a month on how organisations decide on, buy and adopt AI. Unsubscribe at any time.